Search Results

You are looking at 1 - 2 of 2 items for :

  • pharmacokinetics x
  • Psychology, other x
Clear All
Open access
Open access

Matej Stuhec and Jordi Serra-Mestres

to add that there are few possibilities that the inhibition of any single isoform could cause clinically significant changes in the pharmacokinetics of sertraline ( Obach et al. 2005 ). These important pharmacokinetic properties of sertraline show that it has a small number of possible clinically important DDIs in real clinical practice. Despite the fact that these pharmacokinetic properties are important, it is clear that sertraline cannot be used in all older patients on polypharmacy because antidepressants have different mechanisms of action that are very